Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $31.9 million.

  • Lyell Immunopharma's Total Current Liabilities fell 487.59% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year decrease of 487.59%. This contributed to the annual value of $53.8 million for FY2024, which is 5582.14% up from last year.
  • Per Lyell Immunopharma's latest filing, its Total Current Liabilities stood at $31.9 million for Q3 2025, which was down 487.59% from $36.9 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Total Current Liabilities high stood at $63.7 million for Q2 2021, and its period low was $30.8 million during Q1 2023.
  • In the last 5 years, Lyell Immunopharma's Total Current Liabilities had a median value of $37.0 million in 2022 and averaged $41.4 million.
  • In the last 5 years, Lyell Immunopharma's Total Current Liabilities tumbled by 3161.8% in 2023 and then skyrocketed by 5582.14% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Total Current Liabilities (Quarter) stood at $46.7 million in 2021, then decreased by 20.78% to $37.0 million in 2022, then decreased by 6.78% to $34.5 million in 2023, then soared by 55.82% to $53.8 million in 2024, then plummeted by 40.73% to $31.9 million in 2025.
  • Its Total Current Liabilities stands at $31.9 million for Q3 2025, versus $36.9 million for Q2 2025 and $41.3 million for Q1 2025.